Evidence map›Paper›PMID 41239371›Full record

ArticleCardiovascular diabetology2025

A glucose time in range of 70% attenuates the senescence-inducing and pro-inflammatory effects of hyperglycemia.

Rosalba La Grotta, Valeria Pellegrini, Francesca Carreras, Cesare Celeste Berra, Karolina Mužina, Barbara Jenko Bizjan, Klemen Dovc, Francesco Prattichizzo, Tadej Battelino, Antonio Ceriello

Abstract read
In one paragraph

Article in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rosalba La GrottaIRCCS MultiMedica, Polo Scientifico e Tecnologico, Via Fantoli 16/15, 20138, Milan, Italy.
Valeria PellegriniIRCCS MultiMedica, Polo Scientifico e Tecnologico, Via Fantoli 16/15, 20138, Milan, Italy.
Francesca CarrerasIRCCS MultiMedica, Polo Scientifico e Tecnologico, Via Fantoli 16/15, 20138, Milan, Italy.
Cesare Celeste BerraDepartment of Endocrinology and Metabolic Diseases, IRCCS MultiMedica, Milan, Italy.
Karolina MužinaClinical Institute of Special Laboratory Diagnostics, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Barbara Jenko BizjanClinical Institute of Special Laboratory Diagnostics, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Klemen DovcDepartment of Endocrinology, Diabetes and Metabolic Diseases, University Children's Hospital, Ljubljana, Slovenia.
Francesco PrattichizzoIRCCS MultiMedica, Polo Scientifico e Tecnologico, Via Fantoli 16/15, 20138, Milan, Italy. francesco.prattichizzo@multimedica.it.
Tadej Battelino *Department of Endocrinology, Diabetes and Metabolic Diseases, University Children's Hospital, Ljubljana, Slovenia.
Antonio Ceriello *IRCCS MultiMedica, Polo Scientifico e Tecnologico, Via Fantoli 16/15, 20138, Milan, Italy.

Funding

Ministero della Salute Ricerca Corrente to IRCCS MultiMedicaMinistero della Salute SG-2021-12372752Slovenian National Research Agency J3-4528Slovenian National Research Agency P3-0343The Slovenian Research and Innovation Agency J3-4521
6 · The paper itself

Abstract

backgroundThe Time In Range (TIR) represents the amount of time spent by a given individual in the range close to normoglycemia, i.e. 70-180 mg/dl. On the basis of studies demonstrating an association of TIR with the incidence of diabetes complications, guidelines recommend a target of at least 70% of TIR for most people with diabetes. However, no study has explored the effect of variable degrees of TIR on molecular mechanisms relevant for the development of diabetes complications.

methodsWe exposed endothelial cells and monocytes to increasing percentages of TIR, i.e. 50%, 70%, 85% by changing cell media twice a day as appropriate, as well as to constant normoglycemia (i.e. fixed 100 mg/dl of glucose for endothelial cells) and hyperglycemia (i.e. 500 mg/dl glucose), evaluating the development of senescence, of the associated pro-inflammatory response, and monocytes adhesion to endothelial cells as a functional assay. We then assessed the expression of a plethora of markers of senescence and inflammation at the mRNA level in peripheral blood mononuclear cells (PBMC)s derived from individuals with early (i.e. 1-year post-diagnosis) type 1 diabetes (T1D, n = 37), categorized according to the TIR (< or > 70%) observed in the previous 14 days, comparing the two groups through ANCOVA adjusted for HbA1c. As a confirmatory analysis, we also compared the expression of the same markers in people with Time Above Range (TAR), considered as the whole time above 180 mg/dl, ≥ vs < 30%. Correlations between TIR values and the expression of the same markers were tested through linear regression.

resultsConstant hyperglycemia promoted the development of senescence in endothelial cells and induced inflammatory responses in both endothelial cells and monocytes, promoting also monocytes adhesion to endothelial cells. A TIR of 70%, but not of 50%, suppressed these effects while a TIR of 85% did not provide additional benefit. Data from people with T1D mirrored such results, as demonstrated by the higher expression of p16, a marker of senescence, and of IL-6, MCP-1, and CXCL1, three inflammatory mediators, in PBMCs from individuals with TIR < 70% and compared with those with TIR > 70%, independently of HbA1c. Similar results were obtained when comparing people with TAR ≥ vs < 30%. When considered as a continuous variable, TIR values were correlated with p16, IL-6, and CXCL1.

conclusionsA TIR above 70% is associated with attenuated pro-senescence and pro-inflammatory effects of hyperglycemia. These molecular results support the TIR target currently recommended by guidelines, especially for people with T1D.

Indexed as

Blood GlucoseCellular SenescenceDiabetes Mellitus, Type 1Endothelial CellsHyperglycemiaInflammationInflammation MediatorsAdultBiomarkersCell AdhesionCells, CulturedFemaleHumansHuman Umbilical Vein Endothelial CellsMaleMiddle AgedBiomarkersBlood GlucoseInflammation MediatorsContinuous glucose monitoringEndothelial cellsHyperglycemiaInflammationMonocytesPBMCSenescenceTARTIRType 1 diabetes

Identifiers

PMID41239371
PMCPMC12619397

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.